The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRSSF | -10.92% | -90.93% | -38.13% | -39% |
| S&P | +14.08% | +93.57% | +14.12% | +187% |
TerrAscend Corp. produces and sells medical cannabis products. The firm owns several businesses and brands, including The Apothecarium, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections and Arise Bioscience Inc. The company was founded by Basem Hanna, Vijay Sappani and Michael Nashat on March 7, 2017 and is headquartered in Mississauga, Canada.
Cannabis stocks are back in style, but is either one of these multi-state operators a long-term buy?
Could a multi-state operator finally list on a top North American exchange?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $65.10M | -12.2% |
| Gross Profit | $32.47M | -4.5% |
| Gross Margin | 49.87% | 4.0% |
| Market Cap | $251.12M | -33.4% |
| Market Cap / Employee | $0.22M | 0.0% |
| Employees | 1.2K | -0.2% |
| Net Income | -$9.91M | 53.7% |
| EBITDA | $15.48M | 89.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $36.63M | 34.4% |
| Accounts Receivable | $15.57M | -6.8% |
| Inventory | 33.9 | -34.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $242.45M | 3.5% |
| Short Term Debt | $12.16M | 1.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.60% | 2.7% |
| Return On Invested Capital | -31.44% | 35.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.48M | -60.8% |
| Operating Free Cash Flow | $2.74M | 73.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.92 | 0.79 | 0.50 | 2.13 | 27.16% |
| Price to Sales | 0.61 | 0.47 | 0.29 | 0.93 | -20.84% |
| Price to Tangible Book Value | -1.70 | -1.41 | -0.74 | -1.52 | -61.68% |
| Price to Free Cash Flow TTM | 6.70 | 5.98 | 6.51 | 21.78 | 89.04% |
| Enterprise Value to EBITDA | 33.67 | 25.10 | 20.01 | 30.62 | -57.62% |
| Free Cash Flow Yield | 14.9% | 16.7% | 15.4% | 4.6% | -47.10% |
| Return on Equity | -38.3% | -38.8% | -44.5% | -42.8% | 13.45% |
| Total Debt | $246.18M | $245.82M | $242.20M | $254.62M | 3.40% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
